Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents

Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents

Immune therapy improves cancer outcomes, yet many patients do not respond. This pre-clinical study investigated whether vascular disrupting agents (VDAs) could convert an immune unresponsive tumor into a responder. CDF1 mice, with 200 mm<sup>3</sup> C3H mammary carcinomas in the right re...

Full description

Bibliographic Details
Main Authors: Michael R. Horsman, Thomas R. Wittenborn, Patricia S. Nielsen, Pernille B. Elming
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:International Journal of Molecular Sciences
Subjects:
vascular disrupting agents
combretastatin
OXi43503
checkpoint inhibitors
anti-PD-1
anti-PD-L1
Online Access:https://www.mdpi.com/1422-0067/21/13/4778

Internet

https://www.mdpi.com/1422-0067/21/13/4778

Similar Items